Article Text

PDF
Neonatal screening for sickle cell disease in France: evaluation of the selective process
  1. Isabelle Thuret1,2,
  2. Jacques Sarles2,3,
  3. Françoise Merono4,
  4. Eliane Suzineau5,
  5. Jacques Collomb5,
  6. Danielle Lena-Russo4,
  7. Nicolas Levy4,6,
  8. Josiane Bardakdjian7,
  9. Catherine Badens2,4,6
  1. 1Service d'Hématologie Pédiatrique, Hôpital d'enfants de la Timone, Marseille, France
  2. 2Association Régionale de Dépistage et d'Etude des Encéphalopathies et des Affections Génétiques, Hôpital d'enfants de la Timone, Marseille, France
  3. 3Service de Pédiatrie multidisciplinaire, Hôpital d'enfants de la Timone, Marseille, France
  4. 4Centre d'Enseignement et de Recherche en Génétique Médicale, Faculté de Médecine de Marseille, Marseille, France
  5. 5Direction de la Santé, Conseil Général des Bouches du Rhône, Marseille, France
  6. 6Laboratoire de Génétique Moléculaire, Hôpital d'enfants de la Timone, Marseille, France
  7. 7Laboratoire de Biochimie, Hôpital Henri Mondor, Créteil, France
  1. Correspondence to Catherine Badens, Laboratoire de Génétique Moléculaire, Hôpital d'enfants de la Timone, 13385 Marseille Cedex 5, France; badens{at}medecine.univ-mrs.fr

Abstract

Aims The French national programme for neonatal screening of sickle cell disease is applied to newborns ‘at risk’, defined as those born to parents originating from sub-Saharan Africa, the Mediterranean area, the Arabic peninsula, the French overseas islands and the Indian subcontinent. The selection is performed by the nurse in charge of blood sampling by interviewing the mother about the family's geographical origins. The mean rate of testing in France is 25%, ranging from 2% to 50% depending on the region. This study aimed to evaluate the effectiveness of selection during this screening programme.

Methods False-negative cases were identified using two different approaches: first, a regional prospective study aimed at screening all newborns, selected and non-selected, in a restricted area, representing 3% of national births; second, a retrospective national survey to identify false-negative cases.

Results The regional study indicated that selective screening leads to a carrier frequency that is twice as high in the selected population as compared with the non-selected population (1.23% versus 0.62%). The local and national surveys revealed that, during a 6-year period, 28 affected children failed to be selected, leading to a false-negative rate of 2.1%. In contrast to what was expected, most of the cases were due to the failing of the data collection process and not to the misdiagnosis of the risk.

Conclusions These results show that selective neonatal screening for sickle cell disease is feasible if very careful attention is paid to the selective step.

  • Newborn biochemical screening
  • selective neonatal screening
  • sickle cell disease

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Ethics approval This study was conducted with the approval of the Comission éthique de la Société Française de Dépistage et de Prévention des Handicaps de l'Enfant.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.